How has been the historical performance of Ishita Drugs?
Ishita Drugs has shown mixed historical performance, with net sales increasing to 15.00 crore in March 2025, alongside improved profitability metrics, but facing challenges with cash flow and rising liabilities. Total assets and liabilities both grew to 16.30 crore, indicating financial strain despite profit growth.
Answer:The historical performance of Ishita Drugs shows a mixed trend in various financial metrics over the years.Breakdown:
Ishita Drugs' net sales for the year ending March 2025 were reported at 15.00 crore, a slight decrease from 15.19 crore in March 2024, but an increase from 12.07 crore in March 2023. The total operating income mirrored this trend, with a total of 15.00 crore in March 2025 compared to 15.19 crore in the previous year. The company's total expenditure, excluding depreciation, decreased to 14.00 crore in March 2025 from 14.28 crore in March 2024. Consequently, the operating profit (PBDIT) rose to 1.34 crore in March 2025, up from 1.19 crore in March 2024. Profit before tax also increased to 1.16 crore in March 2025 from 0.99 crore in March 2024, leading to a profit after tax of 0.87 crore, compared to 0.75 crore in the previous year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets grew to 16.30 crore in March 2025 from 10.81 crore in March 2024, while total liabilities also increased to 16.30 crore from 10.81 crore. The company reported a cash flow from operating activities of -3.00 crore in March 2025, a decline from 2.00 crore in March 2024, indicating challenges in cash generation despite the increase in profits. Overall, while Ishita Drugs has shown growth in sales and profitability, it faces fluctuations in cash flow and rising liabilities.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
